Anti-CTLA4 agents such as ipilimumab and tremelimumab have shown activity in different cancers, including MSI-H CRC, demonstrating a synergistic, or at least an additive effect when combined with anti-PD(L)1 agents. The gene discussed is CD274; the disease is colorectal carcinoma.